AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of one of the most aggressive cancers – acute myeloid leukaemia (AML).
Bristol-Myers Squibb’s Opdivo and Yervoy has become the first approved immunotherapy combination option for a group of patients with advanced colorectal cancer.
The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma's kidney cancer drug Fotivda, enabling around 165 patients a year to access the treatment.